AngioDynamics (NASDAQ:ANGO) Issues FY 2027 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2027 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.290–0.240 for the period, compared to the consensus estimate of -0.190. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $328.7 million.

AngioDynamics Stock Down 0.2%

AngioDynamics stock opened at $12.77 on Tuesday. The firm has a 50-day moving average price of $12.03 and a two-hundred day moving average price of $11.32. AngioDynamics has a 52-week low of $8.36 and a 52-week high of $13.99. The firm has a market capitalization of $527.66 million, a price-to-earnings ratio of -17.03 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts expect that AngioDynamics will post -0.23 earnings per share for the current year.

Analysts Set New Price Targets

ANGO has been the topic of several recent analyst reports. Canaccord Genuity Group cut their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Zacks Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mercer Global Advisors Inc. ADV lifted its holdings in AngioDynamics by 38.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 14,604 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 4,030 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of AngioDynamics by 69.6% in the 4th quarter. XTX Topco Ltd now owns 40,811 shares of the medical instruments supplier’s stock worth $524,000 after purchasing an additional 16,742 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of AngioDynamics in the 4th quarter worth approximately $463,000. Engineers Gate Manager LP acquired a new stake in AngioDynamics during the fourth quarter valued at approximately $204,000. Finally, AQR Capital Management LLC boosted its holdings in AngioDynamics by 222.8% during the fourth quarter. AQR Capital Management LLC now owns 225,646 shares of the medical instruments supplier’s stock worth $2,897,000 after buying an additional 155,753 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.